Patients with ACA, without established or suspected pulmonary complications, have PFT abnormalities consistent with indolent increased pulmonary vascular resistance despite the majority of such patients not subsequently developing PAH. PubMed, Clin Rheumatol, 2014 Apr 22. (Also see: Scleroderma Autoantibodies and Pulmonary Hypertension Diagnosis)
This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.